source
- Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studiesOno Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…
- Anthropic outlines biopharma strategy ahead of potential record-size IPOAnthropic, the AI startup that recently filed paperwork for what could become the largest initial public offering in business history, used its AI Day event to detail its biopharma ambitions. The…